tiprankstipranks

Arctic Bioscience to Unveil HeROPA Trial Results

Arctic Bioscience to Unveil HeROPA Trial Results

Arctic Bioscience AS (DE:9TD) has released an update.

Arctic Bioscience, a biotech firm focusing on bioactive marine compounds, is set to present results from the HeROPA clinical trial in a webcast on October 16, 2024, led by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. The company is actively developing a new drug, HRO350, aimed at treating mild-to-moderate psoriasis and markets nutraceuticals globally under the ROMEGA® brand.

For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App